“The next big one that comes to the market is adalimumab,” says [Napp Pharmaceutical Group Ltd.]’s director of market access and external affairs Andrew Roberts, when discussing the uptake of monoclonal antibody (MAb) biosimilars in the UK. Currently the biosimilar with the widest distribution in the UK is infliximab, with around 600,000 units distributed a year.
“The NHS policy of savings on medicines has been in place for almost a decade so manufacturers were frustrated that the NHS wasn’t doing more about biosimilars use,” says Roberts. “However, the speed at which policy moved and uptake improved was quite astonishing and over the last 18 months we’ve started to see far less barriers to uptake in the whole of the UK
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?